Integra LifeSciences Holdings (IART) 2020年年度报告「NASDAQ」.pdf

1、Transforming For GrowthAnnual Report2 02 0TO OUR SHAREHOLDERSUndeniably,2020 was a year we will remember a year in which a novel coronavirus pandemic upended communities,businesses and families,and disrupted life as we knew it.As the world managed the impact of this unprecedented event,we quickly ad

2、apted to our new environment.We rapidly organized the way we worked to keep our colleagues safe and to stay connected with customers.We optimized our product portfolio and accelerated our investments to drive future growth.It was inspiring to see Integra colleagues come together and navigate through

3、 this period of uncertainty,emerging with a greater sense of community and absolute determination to succeed.More importantly,our unwavering commitment to serving customers and patients made our recovery possible and our company even stronger.A YEAR LIKE NO OTHERIntegra kicked off the year strong an

4、d on track against our operating plans when the COVID-19 pandemic quickly dis-rupted this growth trajectory and adversely impacted our performance.As COVID-19 reached a tipping point in Europe and the United States during the last two weeks of March,its far-reaching repercussions were felt across ou

5、r industry and our businesses,with hospitals cancelling or postponing elec-tive procedures and eventually deferring certain non-elective procedures.As a result of the pandemic,full-year revenues declined nearly 10 percent to$1.37 billion.Putting the year in perspective,revenues in the first half dec

6、lined 18 percent and adjusted earnings per share declined by over 40 percent com-pared to the same period a year ago.As surgical procedures resumed,we saw a steady improvement in our business in the second half of the year,revenues declined by only 2 percent and adjusted earnings per share rebounded